AKRO - Akero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.82
-0.33 (-1.43%)
As of 12:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close23.15
Open23.19
Bid22.86 x 900
Ask23.21 x 800
Day's Range22.62 - 23.75
52 Week Range16.06 - 34.00
Volume58,818
Avg. Volume162,391
Market Cap651.71M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.60
  • Canaccord: These 3 Stocks Are Poised to Surge by at Least 50%
    TipRanks

    Canaccord: These 3 Stocks Are Poised to Surge by at Least 50%

    The fear of the coronavirus spreading further afield hasn’t dampened investors’ appetite. The major indexes continue to trade at all-time highs, with both the S&P 500 and Nasdaq Composite touching new milestones earlier this week.According to Canaccord's chief market strategist Tony Dwyer there are several reasons the outlook for the markets remains bullish. “You have full employment with easy money and high money availability, high confidence and a millennial demographic that’s going into the household formation years,” he said.With this in mind, we pulled up three of Canaccord’s recent stock picks which the renowned investment firm thinks can soar in the coming months – by over 50% each, as it happens. Just to be safe, we run them through TipRanks Stock Screener tool to ensure that other analysts agree with Canaccord. Let’s take a closer look.SeaSpine Holdings (SPNE)SeaSpine’s 2020 has gotten off to a bright start; the medical device company is up by 36% year-to-date. According to Cannacord’s Kyle Rose, there is yet more to come.SeaSpine designs, develops and sells surgical equipment for the treatment of spinal disorders. The company's ever-expanding portfolio of products has been growing impressively; 22 launches between 2016-2018, 7 more last year and a further 12 expected this year.The global spinal implant market is the largest division within the musculoskeletal space and is worth over $10 billion. The space is ideally suited to smaller, pure play companies such as SeaSpine, as the spine market’s focus on education and physician relationships rewards innovation. The company has strategically invested in its sales arm and has a strong distribution channel, too.Rose sees “smooth sailing and share-taking ahead for SPNE in 2020." The 5-star analyst cites new products, improving distribution and a clean balance sheet as reasons to be optimistic.He said, “SeaSpine management has clearly put an emphasis on new product development in order to differentiate away from an older, legacy portfolio. New, innovative products are not only key to fighting off competitive pressures, but also crucial for retaining the mindshare of distributors as the company works to retain key existing distributors and transition to exclusive relationships that incentivize near and long-term growth.”It's no surprise to learn, then, that Rose initiated coverage of SPNE with a Buy rating. The price target of $25 conveys the analyst’s belief SeaSpine can add an extra 55% to its share price over the next 12 months. (To watch Rose’s track record, click here)The Street adjusts its posture and concurs; SeaSpine’s Moderate Buy consensus rating breaks down into 5 Buys and 1 Sell. At $20.50, the average price target indicates further possible upside of 27%. (See SeaSpine stock analysis on TipRanks)American Superconductor (AMSC)From spinal solutions to solving energy issues, where we come across American Superconductor. The energy technology company designs and manufactures power systems and superconducting wire, providing megawatt-scale solutions across the globe. The company has a two -pronged approach, focusing both on Wind and Grid.According to Canaccord’s Chip Moore, AMSC’s management of power flows are tied to several attractive long-term secular drivers. The 5-star analyst notes that with distributed generation assets on the rise and accelerating adoption of electric vehicles, the need for increased grid reliability is key. AMSC’s REG (Resilient Electric Grid) links together critical substations via its Amperium HTS wire (which allows systems to flexibly redirect power) which, in turn, helps tackle this issue in urban environments. The first key project (ComEd) is making headway in Chicago, with more to come should it prove a success.Moore noted, “We find management making good strides in commercialization of several attractive markets (beyond wind), supporting reduced future volatility and what we view as a path toward sustainable cash generation. With ~$68M of cash and investments on the balance sheet, a more reasonable valuation following last year’s pullback, and a rapidly approaching breakeven (~$25M of sales per quarter), we see good future potential for aggressive growth-type investors.”What does it mean, then? It means the 5-star analyst initiates coverage of AMSC with a Buy rating. Moore sets a price target of $13, indicating potential upside of 65%. (To watch Moore’s track record, click here)The grid is currently operating quietly on the Street, with only one additional analyst chiming in with a view on AMSC’s prospects. The additional Buy, though, means the energy solutions provider rates as a Moderate Buy. With an average price target of $13.5, investors could be pocketing a 72% gain over the coming months. (See American Superconductor stock analysis on TipRanks)Akero Therapeutics (AKRO)This clinical-stage biotech was only founded in 2017 and went public in June of last year. Akero Therapeutics might be a young company but has already been turning heads on the Street; Its share price is up by 54% since its first day on the market.The company’s focus is on the development of medicines to reverse the course of serious metabolic diseases, specifically ones with high unmet medical needs (orphan diseases).Akero’s lead candidate is AKR-001, a treatment for NASH disease (Non-Alcoholic SteatoHepatitis), a fatty liver disease, for which there are currently no specific drugs available. The market for NASH medications is expected to increase considerably over the next few years, and whoever will bring a viable solution to into play stands to cash in handsomely. The drug is currently in a Phase 2 trial with top-line data expected this quarter.Following promising data from a Phase 1 trial, Cannacord’s Edward Nash believes Akero’s AKR-01 “has demonstrated superior molecule design advantages.” Furthermore, the 4-star analyst thinks Akero has an impressive management team with “significant biotech and pharma financing, drug development, regulatory and launch experience.”Nash said, “Our model assumes a NASH population with stage 1-3 fibrosis, a 35% diagnosis rate and 80% treatment rate, resulting in a 2.1M target market eligible for AKR-001 treatment. Assuming a modest 5% penetration rate in 2029, the out-year of our model, and pricing in-line with branded type 2 diabetes medications, we conservatively project Akero to book worldwide revenue of ~$1.1B. With ~$148M in cash and equivalents reported at the end of 3Q19 we believe the company is well capitalized to achieve meaningful clinical milestones before funding is required.”Accordingly, Nash initiated coverage on the NASH fighter with a Buy rating and a $36 price target. The potential upside, should the target be met, comes in at 52%. (To watch Nash’s track record, click here)What does the Street think of Akero’s prospects? The sole Buy ratings – 5, in fact – bestow a Strong Buy consensus rating on the promising biotech. With an average price target of $32.8, analysts see the potential for a 31% increase to the share price over the coming year. (See Akero stock analysis on TipRanks)

  • Quench Bio launches with $50M to treat 'missing link' to inflammatory disease
    American City Business Journals

    Quench Bio launches with $50M to treat 'missing link' to inflammatory disease

    What do fatty liver disease, asthma and a rare genetic condition called Familial Mediterranean Fever have in common? A newly launched biotech company believes they can all be treated with one approach.

  • Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
    PR Newswire

    Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

    Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that the ongoing Phase 2a BALANCED study of AKR-001 is being expanded to include an additional cohort of subjects with NASH who have compensated cirrhosis (F4), Child-Pugh Class A.

  • Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference
    PR Newswire

    Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

    Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that CEO Andrew Cheng, M.D., Ph.D., will provide a business overview and update at the J.P. Morgan Healthcare Conference at 7:30 AM Pacific time on Wednesday, January 15, 2020.

  • 4 More Biotechs With Blockbuster Potential
    GuruFocus.com

    4 More Biotechs With Blockbuster Potential

    Akero, Dermira, Global Blood Therapeutics and Moderna all have drugs that could hit $1 billion in sales Continue reading...

  • Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
    PR Newswire

    Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

    Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that it has completed enrollment in the Phase 2a BALANCED study of AKR-001, a novel FGF21 analog, for the treatment of NASH.

  • Hedge Funds Are Dumping Akero Therapeutics, Inc. (AKRO)
    Insider Monkey

    Hedge Funds Are Dumping Akero Therapeutics, Inc. (AKRO)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
    PR Newswire

    Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis ...

  • Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results
    PR Newswire

    Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results

    SAN FRANCISCO , Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis ...

  • PR Newswire

    InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform

    Participation in event sets stage for ongoing partnerships and engagement with researchers and drug developers based in China SCHLIEREN, Switzerland , Nov. 4, 2019 /PRNewswire/ --  InSphero AG  today announced ...

  • Hedge Funds Have Never Been This Bullish On Akero Therapeutics, Inc. (AKRO)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Akero Therapeutics, Inc. (AKRO)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • Does Akero Therapeutics, Inc. (NASDAQ:AKRO) Need To Raise More Cash?
    Simply Wall St.

    Does Akero Therapeutics, Inc. (NASDAQ:AKRO) Need To Raise More Cash?

    As the US$543m market cap Akero Therapeutics, Inc. (NASDAQ:AKRO) released another year of negative earnings, investors...

  • Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference
    PR Newswire

    Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference

    SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis ...

  • Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
    PR Newswire

    Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results

    -- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggregate net proceeds from Initial Public Offering -- SAN FRANCISCO , Aug. 12, 2019 /PRNewswire/ -- Akero ...

  • Benzinga

    The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) ...

  • PR Newswire

    Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)

    SAN FRANCISCO, July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study). "Akero's AKR-001 clinical program is progressing as planned and we remain on track to report study results in the first half of 2020," said Kitty Yale, Chief Development Officer, Akero Therapeutics.

  • PR Newswire

    Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

    SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis ...

  • Benzinga

    Akero Therapeutics IPO Opens Above IPO Price

    Akero Therapeutics (NASDAQ: AKRO ) shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16. Akero was founded in January 2017 and focuses on developing transformative ...

  • PR Newswire

    Akero Therapeutics Announces Pricing of Initial Public Offering

    SAN FRANCISCO , June 19, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis ...

  • Benzinga

    Akero Therapeutics IPO: What You Need To Know

    A slew of biotech issues hit the Street this week. Akero Therapeutics, Inc, a South San Francisco, California-based clinical-stage biotech, is planning a 5-million share IPO, with the offering estimated to be priced between $14 and $16, according to the S-1/A filing from June 10. The company has applied for listing on the Nasdaq under the ticker symbol AKRO.

  • Benzinga

    IPO Outlook For The Week: Biotechs And A Grocery Outlet

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...